Beranda › Leukemia Limfositik Kronis › Oregon
Uji klinis Leukemia Limfositik Kronis di Oregon
16 studi untuk Leukemia Limfositik Kronis mencari peserta di lokasi di Oregon.
Kota di Oregon
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- dan 1 lainnya
Menerima pesertaFase 3
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- dan 7 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Saint Charles Health System, Bend
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06846671A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Oregon Health and Science University ( Site 5425), Portland
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05947851Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06784167A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Portland
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06564038Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Oncology Associates of Oregon, Eugene
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07520006Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Williamette Valley Cancer Institute & Research Center, Eugene
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Willamette Valley Cancer Institute and Research Center /ID# 266326, Eugene
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06428019Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT05544019Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- OHSU Knight Cancer Institute, Portland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Nov 2025 · NCT05943496A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2025 · NCT05780034Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.